Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0.00666666666666667 0.00666666666666667 -0.00166666666666663
Stock impact report

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

Monte Rosa Therapeutics, Inc. (GLUE) 
Company Research Source: GlobeNewswire
Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025 Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases driven by IL-1ß and the NLRP3 inflammasome, on track for IND filing in H1 2025 Year-end cash and equivalents expected to be $377 million as of December 31, 2024 (unaudited) and anticipated to fund operations into 2028 through multiple anticipated proof-of-concept clinical readouts Company to present at J.P. Morgan Healthcare Conference on Tuesday, January 14, at 5:15 p.m. PST BOSTON, Jan. 10, 2025 (GLOBE NEW Read more
Impact Snapshot
Event Time:
GLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Created with Highstock 5.0.1230sec1m5m10m30m60m90m120m-0.25%0.00%0.25%0.50%0.75%
Opt-in for
GLUE alerts

from News Quantified
Opt-in for
GLUE alerts

from News Quantified